FDA Approves Immune-Oncology Combination for Melanoma
the ONA take:
The US Food and Drug Administration (FDA) has granted accelerated approval to a regimen consisting of nivolumab and ipilimumab for the treatment of patients with BRAF V600 wild-type unresectable or metastatic melanoma.
Nivolumab should be administered at a dose of 1 mg/kg intravenously over 60 minutes, followed by ipilimumab 3 mg/kg intravenously on the same day, every 3 weeks for four doses, then nivolumab 3 mg/kg over 60 minutes every 2 weeks until disease progression or unacceptable toxicity.
In regard to safety, the most common adverse reactions in patients receiving the combination in clinical trials were rash, pruritus, headache, vomiting, and colitis.
The most frequent grade 3 or 4 laboratory abnormalities were increased ALT, increased AST, increased lipase, increased amylase, hyponatremia, and lymphopenia.
Health care professionals should monitor for changes in liver function, renal function, and thyroid function.
The regimen was evaluated in 142 patients with unresectable or metastatic melanoma. Participants were randomly assigned to receive nivolumab plus ipilimumab or ipilimumab alone.
Results showed that the combination stopped cancer progression in 60% of patients with BRAF V600 wild-type disease compared with 11% in the ipilimumab alone arm.
Both drugs are also approved as monotherapy for the treatment of unresectable or metastatic melanoma.
Accelerated approval for nivolumab and ipilimumab for the treatment of patients with BRAF V600 wild-type unresectable or metastatic melanoma.
- Novel Colonoscopy Prep Is Poised to Improve Screening Rates for Colon Cancer
- PPIs Negatively Impact Outcomes of Patients Treated With Capecitabine
- How Physical Changes From Breast Cancer Affect Self-Image: Considerations for Clinicians
- Panobinostat Modestly Improves OS in Relapsed Multiple Myeloma
- Short-Term Intervention May Have Long-term Diet Effect in Hispanic Breast Cancer Survivors
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Implementing a Distress Screening Process for Cancer Patients
- Initiating Palliative Care in the Emergency Department
- New Research Identifies Potential Bladder Cancer Chemotherapy Side Effect
- Pseudohyperkalemia: False Potassium Levels Occur in a Patient With Lymphoma
- Atezolizumab Granted FDA Approval for Specific Cases of NSCLC
- Low-Dose Sublingual Fentanyl Safe, Effective in Patients Receiving Lower Opioid Doses
- High U.S. Economic Burden for Vaccine-Preventable Diseases
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|